Should You Buy Cassava Sciences Stock Now?

1 min read

Shares of Alzheimer’s disease drug developer Cassava Sciences (NASDAQ: SAVA) have soared this year thanks to progress with a potential new drug called sumifilam. This is a big deal, because there still aren’t any available treatments for the progressive and ultimately fatal condition that affects more than 5 million Americans.

Does simufilam have a clear enough shot at success to make Cassava Sciences a smart investment right now? To find out, we’ll need to weigh compelling reasons to buy this stock against reasons to remain cautious.

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

3 Stocks We Bought in the Tech Sell-Off

Next Story

Target Stock Is Still a Buy

Latest from Blog